Professional
Added to YB: 2025-03-21
Pitch date: 2024-12-31
LLY [bullish]
Eli Lilly and Company
+37.09%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$920.0B
Pitch Price
$774.81
Price Target
N/A
Dividend
0.67%
EV/EBITDA
32.91
P/E
50.26
EV/Sales
16.03
Sector
Pharmaceuticals
Category
growth
Show full summary:
Parnassus Core Equity Fund New Position: Eli Lilly and Company
LLY (new position): Global pharma with strong GLP-1 franchise & innovation track record. Revenue miss & Trump health sec nominee caused sell-off. Opportunity to gain exposure to attractive product suite & pipeline at good valuation. Positioned for long-term growth.
Read full article (1 min)